Tags

Type your tag names separated by a space and hit enter

Developing therapeutics for the diseases of protein misfolding.

Abstract

Our current structural and biologic understanding of the misfolding diseases has restricted the development of therapies that target these diseases at a molecular level. The prion diseases are illustrative of this group of misfolding disorders and provide a model system for therapeutic intervention. Strategies to inhibit the replication and accumulation of the prion protein are being developed and have entered animal and clinical studies. Due to the underlying molecular basis of this disease class, many of the therapeutic approaches used to target prion misfolding have parallels in other misfolding diseases.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94143-2240, USA. alchemi@itsa.ucsf.edu

    ,

    Source

    Neurology 66:2 Suppl 1 2006 Jan 24 pg S118-22

    MeSH

    Alzheimer Disease
    Amyotrophic Lateral Sclerosis
    Diabetes Mellitus, Type 2
    Drug Design
    Humans
    Huntington Disease
    Immunization, Passive
    Kinetics
    Molecular Structure
    Mutation
    Nerve Tissue Proteins
    Neurodegenerative Diseases
    Parkinson Disease
    PrPSc Proteins
    Prion Diseases
    Protein Conformation
    Protein Folding
    Protein Structure, Secondary

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    16432139

    Citation

    May, Barnaby C H., et al. "Developing Therapeutics for the Diseases of Protein Misfolding." Neurology, vol. 66, no. 2 Suppl 1, 2006, pp. S118-22.
    May BC, Govaerts C, Cohen FE. Developing therapeutics for the diseases of protein misfolding. Neurology. 2006;66(2 Suppl 1):S118-22.
    May, B. C., Govaerts, C., & Cohen, F. E. (2006). Developing therapeutics for the diseases of protein misfolding. Neurology, 66(2 Suppl 1), pp. S118-22.
    May BC, Govaerts C, Cohen FE. Developing Therapeutics for the Diseases of Protein Misfolding. Neurology. 2006 Jan 24;66(2 Suppl 1):S118-22. PubMed PMID: 16432139.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Developing therapeutics for the diseases of protein misfolding. AU - May,Barnaby C H, AU - Govaerts,Cedric, AU - Cohen,Fred E, PY - 2006/1/25/pubmed PY - 2006/3/10/medline PY - 2006/1/25/entrez SP - S118 EP - 22 JF - Neurology JO - Neurology VL - 66 IS - 2 Suppl 1 N2 - Our current structural and biologic understanding of the misfolding diseases has restricted the development of therapies that target these diseases at a molecular level. The prion diseases are illustrative of this group of misfolding disorders and provide a model system for therapeutic intervention. Strategies to inhibit the replication and accumulation of the prion protein are being developed and have entered animal and clinical studies. Due to the underlying molecular basis of this disease class, many of the therapeutic approaches used to target prion misfolding have parallels in other misfolding diseases. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/16432139/Developing_therapeutics_for_the_diseases_of_protein_misfolding_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=16432139 DB - PRIME DP - Unbound Medicine ER -